Aclaris Therapeutics announced positive phase 1b proof-of-concept results for ATI-052, an investigational bispecific antibody ...
Patients on Medicare often do everything insurers ask, including trying and failing the standard topicals, and still can’t ...
Experts outline how to recognize undertreated psoriasis, assess incomplete response, and make individualized decisions when escalating therapy. The treatment landscape for psoriasis has changed ...
Treatment success in alopecia areata extends beyond a SALT score. Dr. Ungar reviews patient-reported outcome data and describes how he sets timelines for judging response and deciding when to switch.
Aldredge called Horizons in Advanced Practice one of the most profound meetings for newer dermatology NPs and PAs. The intimate audience setting gives attendees access to updated, evidence-based ...
Oral JAK inhibitors are preferred first-line long-term therapy for severe adult AA; FDA-approved agents are favored, whereas dupilumab is an alternative for patients with comorbid atopy. Experts ...
One of the most common misconceptions Feldman encounters among patients and caregivers is that eczema is simply a problem of ...
The FDA has accepted Lynch Regenerative Medicine’s (LRM) investigational new drug (IND) application for a phase 2b clinical ...
In "Transitioning From Self-Injection to HCP-Administered Psoriasis Therapy," our experts examine what to do when a patient ...
ORKA-001 achieved PASI 100 in 61% of high-dose patients at week 16 in the phase 2b EVERLAST-B trial of moderate-to-severe ...
Lutikizumab (ABT-981) met its primary end point and all 8 ranked secondary end points in the phase 3 INTREPID trial ...
Menopause can bring dryness, sensitivity, acne, and loss of firmness, requiring dermatologists to adapt skin care to patients ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results